The CXCL12/CXCR4 axis is therefore a promising drug target in RA, and treatment of mice with collagen-induced arthritis with the CXCR4-specific antagonist AMD3100 was shown to reduce disease severity (148). Here, CXCL12 is linked to rheumatoid arthritis.